Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Exelixis, Inc. stock logo
EXEL
Exelixis
$33.20
+2.3%
$26.81
$19.20
$33.60
$9.47B0.542.06 million shs4.42 million shs
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$140.29
-1.5%
$145.24
$111.83
$150.57
$7.09B0.841.45 million shs1.65 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$838.20
-9.2%
$1,072.53
$772.84
$1,211.20
$92.40B0.12514,941 shs2.29 million shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$475.98
+0.2%
$474.81
$341.90
$510.64
$122.85B0.41.17 million shs1.38 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Exelixis, Inc. stock logo
EXEL
Exelixis
+12.91%+14.55%+25.01%+33.94%+57.55%
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
-0.01%+0.18%-2.19%-3.19%+25.27%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
-0.49%-1.98%-12.22%-15.58%+18.32%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
+1.00%+1.07%+2.15%-6.07%+31.20%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Exelixis, Inc. stock logo
EXEL
Exelixis
4.6634 of 5 stars
2.33.00.04.33.12.53.1
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/AN/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
4.8436 of 5 stars
4.44.00.02.33.02.51.9
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
3.4386 of 5 stars
2.22.00.03.32.52.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Exelixis, Inc. stock logo
EXEL
Exelixis
2.65
Moderate Buy$31.44-5.29% Downside
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
0.00
N/A$167.7219.56% Upside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.73
Moderate Buy$1,101.0031.35% Upside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.48
Hold$492.503.47% Upside

Current Analyst Ratings

Latest IBB, REGN, VRTX, and EXEL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/30/2024
Exelixis, Inc. stock logo
EXEL
Exelixis
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$23.00 ➝ $29.00
10/30/2024
Exelixis, Inc. stock logo
EXEL
Exelixis
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$32.00 ➝ $33.00
10/30/2024
Exelixis, Inc. stock logo
EXEL
Exelixis
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$33.00 ➝ $36.00
10/30/2024
Exelixis, Inc. stock logo
EXEL
Exelixis
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.00
10/30/2024
Exelixis, Inc. stock logo
EXEL
Exelixis
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$32.00 ➝ $36.00
10/30/2024
Exelixis, Inc. stock logo
EXEL
Exelixis
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$33.00 ➝ $38.00
10/30/2024
Exelixis, Inc. stock logo
EXEL
Exelixis
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$29.00 ➝ $36.00
10/30/2024
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$550.00 ➝ $540.00
10/24/2024
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$1,250.00 ➝ $1,175.00
10/24/2024
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$1,200.00 ➝ $1,150.00
10/23/2024
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1,015.00 ➝ $1,015.00
(Data available from 10/31/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.01B4.70$0.89 per share37.44$7.47 per share4.44
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$13.49B6.85$38.88 per share21.56$236.63 per share3.54
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$10.34B11.88$14.60 per share32.60$68.22 per share6.98

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Exelixis, Inc. stock logo
EXEL
Exelixis
$207.76M$1.1628.6220.370.6117.38%15.54%11.97%2/4/2025 (Estimated)
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/A0.00N/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.95B$37.7622.2021.183.2032.04%16.80%13.13%10/31/2024 (Confirmed)
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$3.62B-$2.03N/A29.69N/A-4.74%-2.45%-1.87%11/4/2024 (Confirmed)

Latest IBB, REGN, VRTX, and EXEL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2024N/A
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$3.60N/A-$3.60N/AN/AN/A  
10/31/2024N/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$10.04$12.46+$2.42N/A$3.67 billion$3.72 billion  
8/6/2024Q2 2024
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.31$0.75+$0.44$0.73$468.21 million$637.18 million
8/1/2024Q2 2024
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$8.93$11.56+$2.63$7.79$3.38 billion$3.55 billion    
8/1/2024Q2 2024
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
-$12.54-$12.83-$0.29-$12.62$2.66 billion$2.65 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$0.450.32%N/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
N/AN/AN/AN/AN/A
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A

Latest IBB, REGN, VRTX, and EXEL Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/24/2024
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
$0.20059/25/20249/25/20249/30/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
4.27
4.21
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.10
5.44
4.62
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.02
2.52
2.26

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
62.45%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
90.96%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,310285.25 million277.12 millionOptionable
iShares Biotechnology ETF stock logo
IBB
iShares Biotechnology ETF
N/A50.55 millionN/AOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
13,450110.24 million101.99 millionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
5,400258.10 million257.59 millionOptionable

IBB, REGN, VRTX, and EXEL Headlines

Recent News About These Companies

Oppenheimer Remains a Buy on Vertex Pharmaceuticals (VRTX)
Top Stocks To Buy Now? 2 Biotech Stocks To Watch
Vertex Pharmaceuticals (VRTX) Scheduled to Post Earnings on Monday
Zacks Research Issues Pessimistic Forecast for VRTX Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Exelixis logo

Exelixis

NASDAQ:EXEL
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
iShares Biotechnology ETF logo

iShares Biotechnology ETF

NASDAQ:IBB
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors, which is indirectly owned by BlackRock, Inc.
Regeneron Pharmaceuticals logo

Regeneron Pharmaceuticals

NASDAQ:REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Vertex Pharmaceuticals logo

Vertex Pharmaceuticals

NASDAQ:VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.